Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The payment is in accordance with the agreed contractual terms
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Subscribe To Our Newsletter & Stay Updated